Clinuvel Pharmaceuticals Limited (CLVLF)
OTCMKTS
· Delayed Price · Currency is USD
6.95
-0.35 (-4.79%)
May 2, 2025, 4:00 PM EDT
Clinuvel Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | May '25 May 2, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
Market Capitalization | 366 | 514 | 588 | 506 | 1,137 | 875 | Upgrade
|
Market Cap Growth | -31.82% | -12.65% | 16.31% | -55.55% | 29.97% | -24.32% | Upgrade
|
Enterprise Value | 238 | 398 | 495 | 438 | 1,084 | 836 | Upgrade
|
Last Close Price | 6.95 | 10.07 | 11.96 | 9.72 | 21.41 | 17.06 | Upgrade
|
PE Ratio | 15.25 | 21.60 | 28.87 | 35.14 | 61.34 | 84.20 | Upgrade
|
PS Ratio | 6.50 | 8.73 | 11.28 | 11.16 | 31.39 | 38.92 | Upgrade
|
PB Ratio | 2.72 | 3.79 | 5.37 | 5.84 | 15.36 | 17.59 | Upgrade
|
P/TBV Ratio | 2.72 | 3.80 | 5.37 | 5.85 | 15.39 | 17.63 | Upgrade
|
P/FCF Ratio | 25.17 | 24.46 | 24.62 | 18.61 | 82.41 | 95.30 | Upgrade
|
P/OCF Ratio | 24.82 | 20.77 | 23.93 | 18.40 | 78.75 | 89.33 | Upgrade
|
EV/Sales Ratio | 4.04 | 6.76 | 9.50 | 9.68 | 29.91 | 37.16 | Upgrade
|
EV/EBITDA Ratio | 7.06 | 12.09 | 16.71 | 17.68 | 49.73 | 97.48 | Upgrade
|
EV/EBIT Ratio | 7.22 | 12.28 | 16.86 | 17.89 | 50.60 | 98.79 | Upgrade
|
EV/FCF Ratio | 16.37 | 18.95 | 20.73 | 16.13 | 78.52 | 91.00 | Upgrade
|
Debt / Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade
|
Debt / EBITDA Ratio | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | 0.10 | Upgrade
|
Debt / FCF Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.10 | Upgrade
|
Asset Turnover | 0.41 | 0.42 | 0.46 | 0.52 | 0.51 | 0.45 | Upgrade
|
Inventory Turnover | 0.76 | 0.77 | 1.33 | 3.69 | 1.87 | 4.26 | Upgrade
|
Quick Ratio | 16.37 | 8.33 | 7.02 | 10.03 | 11.35 | 8.88 | Upgrade
|
Current Ratio | 17.37 | 8.81 | 7.44 | 10.24 | 11.81 | 9.10 | Upgrade
|
Return on Equity (ROE) | 19.59% | 19.39% | 21.09% | 18.62% | 28.95% | 23.29% | Upgrade
|
Return on Assets (ROA) | 14.22% | 14.29% | 16.34% | 17.60% | 18.78% | 10.64% | Upgrade
|
Return on Capital (ROIC) | 16.01% | 16.43% | 18.86% | 19.59% | 20.59% | 11.69% | Upgrade
|
Return on Capital Employed (ROCE) | 22.80% | 23.60% | 26.20% | 27.30% | 28.60% | 16.70% | Upgrade
|
Earnings Yield | 6.56% | 4.63% | 3.46% | 2.84% | 1.63% | 1.19% | Upgrade
|
FCF Yield | 3.97% | 4.09% | 4.06% | 5.38% | 1.21% | 1.05% | Upgrade
|
Dividend Yield | 0.48% | 0.33% | 0.28% | 0.28% | 0.09% | 0.10% | Upgrade
|
Payout Ratio | 6.46% | 6.93% | 6.46% | 5.92% | 5.00% | 8.13% | Upgrade
|
Buyback Yield / Dilution | 2.63% | 1.52% | -0.08% | -1.26% | -1.33% | -1.73% | Upgrade
|
Total Shareholder Return | 3.11% | 1.85% | 0.20% | -0.98% | -1.24% | -1.63% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.